Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical-stage natural psychedelic drug development company, today announced that it has been issued a third patent by the United States Patent and Trademark Office for the extraction and standardization of natural psilocybin and associated psychedelic compounds. The patent describes essential technology for transforming psychedelic raw materials into pharmaceutical-grade, standardized drug candidates.

“The continued growth of Filament’s American patent portfolio is a testament to the strength of our drug development platform,” “This approval represents the viability of our IP strategy in the US in addition to our success in Canada.”

Benjamin Lightburn, Chief Executive Officer

Filament has developed innovative technology to extract and standardize stable doses of natural compounds from magic mushrooms. The Company now holds seven patents, four in Canada and three in the United States, including the first-ever patent for the extraction and standardization of natural psilocybin which was issued on August 3, 2021.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.